Bayer for ProfessionalsYour Resource Portal

PP-PF-OTH-GB-0051 | February 2024

Explore BayerPRO Events & Webinars

Cardiovascular

Nephrology

Oncology

Women's Health

Quick Watch

Chronic Kidney Disease Bitesize Videos

Kerendia®▼ (finerenone)

Kerendia UK Prescribing Information

PP-KER-GB-0565, February 2024

Kerendia®▼ (finerenone) Short Videos

Kerendia UK Prescribing Information

PP-KER-GB-0566, March 2024

Oncology Events & Webinars

BOPA 2021

NUBEQA®▼ (darolutamide)

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1299, February 2024

BAUS 2022: Navigating treatment decisions in nmCRPC patients

NUBEQA®▼ (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-1298, February 2024

The evolving nmCRPC treatment landscape

NUBEQA®▼ (darolutamide)

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1320, February 2024

BAUS 2023: When and how to treat prostate cancer?

NUBEQA®▼ (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-1300, February 2024

Women's Health Events & Webinars

How to manage heavy menstrual bleeding (HMB) in community...

It's important to Discuss the symptoms, Check and diagnose, Treat it

Qlaira® Prescribing Information

Mirena® Prescribing Information

PP-PF-WHC-IUS-GB-0059, February 2024

How to develop a sustainable women’s health service

Running an IUD/S service, managing capacity and supporting the IUT fitter

PP-PF-WHC-IUS-GB-0058, February 2024

Vulvovaginal issues in later life

Gain confidence in the management of Genitourinary Syndrome of Menopause (GSM)

PP-PF-WHC-IUS-GB-0057, February 2024

Choosing and using progestogens through the menopause

Identifying perimenopause, Endometrial protection and the role of progesterone during oestrogen replacement. Jaydess®...

Kyleena® Prescribing Information

Mirena® Prescribing Information

Jaydess® ▼ Prescribing Information

PP-PF-WHC-IUS-GB-0056, February 2024

Cardiology Events & Webinars

Common Questions in the treatment of Venous Thromboembolism

Karen Breen

Xarelto® Prescribing Information

RP-XAR-GB-5151, February 2024

What are the key questions for Cancer Associated Thrombosis?

Dr Mari Thomas

Xarelto® Prescribing information

RP-XAR-GB-5149, February 2024

Video Resources on the topic of Venous Thromboembolism (VTE)

Expert advice in the management of VTE from National and International thought leaders

Xarelto® Prescribing Information

RP-XAR-GB-5156, February 2024

Common questions in the treatment of VTE

Dr Mari Thomas talks about the treatment of VTE in a series of short videos

Xarelto® (rivaroxaban) Prescribing Information

RP-XAR-GB-5302, February 2024

Nephrology Events & Webinars

Kerendia®▼ (finerenone) Short Videos

Kerendia UK Prescribing Information

PP-KER-GB-0566, March 2024

Chronic Kidney Disease Bitesize Videos

Kerendia®▼ (finerenone)

Kerendia UK Prescribing Information

PP-KER-GB-0565, February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.